THE TAPE
DOC · REITs · $13.7B

Healthpeak Properties, Inc.

$19.84▼ −0.70%
Last close
Relative strength
49RS
of 99, against every stock▲ +8 on the month
Turning up
Stock-specific strength
+4.4%
six months against REITs
52-week range
−13.6%
from the high
$15.70$22.95
Setup
multi yearplayed out
−9.1%
against the pivot at $21.83
No report date on the calendar.
Growth FLATProof SHOWN
Quarter to Sep 30, revenue +16% on a year ago
11/16 O 20.04 H 20.06 L 19.63 Vol 4.6M
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

RS49
vs pivot−9.12%
Tightening0.93×
Dry-up0.68×
Up/down vol-0.03
From high14%
played out3 of 9checks
Turning up
Support and resistance
Support below
$19.13
-3.6% · tested 4× · last 21 sessions ago
Resistance above
$20.56
+3.6% · tested 4× · last 42 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 77.2 weeks and fell 28% from its ceiling at its deepest. The pivot is $21.83, and the stock closed 9.1% below it. Its relative strength rating is 49.

Against its industry
Stock-specific strengthAhead of its industry over all three, in an industry that is behind the S&P 500 over six months: strength the group does not share.
One month against its industry
+1.4%
Three months against its industry
+2.6%
Six months against its industry
+4.4%

Read against an equal-weighted index of REITs, which is -2.6% against the S&P 500 over six months Not aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap
32
days
Ex-dividend in 32 days
Dec 18, 2026
  1. Ex-dividendconfirmedin 32d
    Ex-dividend date
    Dec 18, 2026
How it moves on earnings

On average 5.5% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$3.1B
+16.3% year on year
Operating margin
—
Net margin
12.3%
Free cash flow
$1.3B
9.3% of market cap
Price to sales
4.46×
Price to earnings
36.2×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 2
Key takeaway
Profitable and cash generating; the question is growth.
Revenue
$820.9M
+6.4% QoQ · +16.3% YoY
Gross margin
—
Net income
$17.3M
Positive
Free cash flow
$354.5M
Cash generating

What the numbers say

  • Revenue +16.3% year over year, +6.4% on the quarter
  • Good: Profitable: net income $17M
  • Good: Cash generating: operating cash flow $354M, free cash flow $354M
  • Weak: Net debt $8.87B · cash $514M
Revenue by quarter
Free cash flow
Net income
shares -0.8% in a year · net debt $8.9B
Final read
Growth: FLAT · Economic proof: SHOWN
Key question: Can the cash generation hold as growth slows?
The next test is the balance sheet: net debt $8.87B · cash $514M.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 2 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 bought new, 1 added.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Reported resultsFiling · 2026-11-03
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Earnings comingEvent · 2026-10-20
reports 2026-10-21
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
Unusual volumeTape · 2026-10-09
3.6 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Unusual volumeTape · 2026-09-19
5.0 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
1
$127,070 total

Sold: Patadia Ankit B..

Not counted above: 13 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-13 Thomas John T · Directorgift12,350
2026-11-09 Patadia Ankit B. · EVP and Treasurersell6,115$127,070
2026-05-29 Thomas John T · Directoraward1,385$21,414
2026-05-29 Thomas John T · Directorwithheld for tax78$1,494
2026-05-29 Patadia Ankit B. · EVP and Treasureraward1,358$20,997
2026-05-29 Patadia Ankit B. · EVP and Treasurerwithheld for tax94$1,800
2026-05-29 Moses Kelvin O · Chief Financial Officeraward937$14,487
2026-05-29 Moses Kelvin O · Chief Financial Officerwithheld for tax65$1,245

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What lines up

3 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy3
Buy5
Hold14
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

Checking your subscription…

X-ray

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Healthpeak Properties, Inc. (DOC) — The Tape